249 related articles for article (PubMed ID: 25420617)
1. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.
Grisendi G; Spano C; D'souza N; Rasini V; Veronesi E; Prapa M; Petrachi T; Piccinno S; Rossignoli F; Burns JS; Fiorcari S; Granchi D; Baldini N; Horwitz EM; Guarneri V; Conte P; Paolucci P; Dominici M
Stem Cells; 2015 Mar; 33(3):859-69. PubMed ID: 25420617
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
3. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
[TBL] [Abstract][Full Text] [Related]
4. TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.
Guiho R; Biteau K; Grisendi G; Taurelle J; Chatelais M; Gantier M; Heymann D; Dominici M; Redini F
Int J Cancer; 2016 Dec; 139(12):2802-2811. PubMed ID: 27558972
[TBL] [Abstract][Full Text] [Related]
5. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.
Guiho R; Biteau K; Grisendi G; Chatelais M; Brion R; Taurelle J; Renault S; Heymann D; Dominici M; Redini F
Cytotherapy; 2018 Aug; 20(8):1037-1045. PubMed ID: 30093324
[TBL] [Abstract][Full Text] [Related]
7. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
Lissat A; Vraetz T; Tsokos M; Klein R; Braun M; Koutelia N; Fisch P; Romero ME; Long L; Noellke P; Mackall CL; Niemeyer CM; Kontny U
Am J Pathol; 2007 Jun; 170(6):1917-30. PubMed ID: 17525260
[TBL] [Abstract][Full Text] [Related]
9. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.
Gamie Z; Kapriniotis K; Papanikolaou D; Haagensen E; Da Conceicao Ribeiro R; Dalgarno K; Krippner-Heidenreich A; Gerrand C; Tsiridis E; Rankin KS
Cancer Lett; 2017 Nov; 409():66-80. PubMed ID: 28888998
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
[TBL] [Abstract][Full Text] [Related]
11. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK.
Kim SW; Kim SJ; Park SH; Yang HG; Kang MC; Choi YW; Kim SM; Jeun SS; Sung YC
Clin Cancer Res; 2013 Jan; 19(2):415-27. PubMed ID: 23204131
[TBL] [Abstract][Full Text] [Related]
12. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
13. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
14. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells.
Xia P; Wang W; Bai Y
Apoptosis; 2014 Mar; 19(3):491-505. PubMed ID: 24242915
[TBL] [Abstract][Full Text] [Related]
15. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
Merchant MS; Yang X; Melchionda F; Romero M; Klein R; Thiele CJ; Tsokos M; Kontny HU; Mackall CL
Cancer Res; 2004 Nov; 64(22):8349-56. PubMed ID: 15548704
[TBL] [Abstract][Full Text] [Related]
17. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.
Xia L; Peng R; Leng W; Jia R; Zeng X; Yang X; Fan M
J Dent Res; 2015 Jan; 94(1):219-28. PubMed ID: 25391621
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
20. A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.
Picarda G; Surget S; Guiho R; Téletchéa S; Berreur M; Tirode F; Pellat-Deceunynck C; Heymann D; Trichet V; Rédini F
Mol Cancer Res; 2012 Mar; 10(3):336-46. PubMed ID: 22258765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]